Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma

Abstract

AbstractBackgroundStudies have shown that the quantification of circulating clonal plasma cells (cCPCs) in peripheral blood using flow cytometry could be used as a prognostic predictor of poor outcome in multiple myeloma (MM).MethodsIn 66 newly diagnosed MM, cCPCs were quantified (cCPC%) and analysed for association with outcome and survival. Single‐tube combined surface (CD45/CD19/CD138/CD38/CD56/CD27/CD81 as per availability) and cytoplasmic (kappa/lambda) staining was done using pre‐titrated volumes of antibodies. In 26 patients, repeat cCPC% was assessed post‐induction therapy. For association studies, treatment response has been taken as good (VGPR and above) and poor (PR and below). All statistical analyses were performed with SPSS software version 16.0.ResultsThere was no significant association between cCPC% at baseline with staging (p = 0.43), β2‐microglobulin (p = 0.27) and albumin (p = 0.08). There was a significant difference between the pre‐induction and post‐induction cCPC% (p = 0.0001). The patients were segregated using a cut‐off of ≥0.197 and <0.197 based on the median values of baseline cCPC%. The post‐induction outcome was available for 47 patients among whom 33 (70%) had VGPR and above. There was a significant association between higher cCPC% at baseline with poor treatment response (p = 0.008). The median OS in the study patients was 42 (CI 28.14–43.03) months and the median PFS was 39 (CI 28.49–49.04) months. Higher cCPC% showed a lower median PFS (30 vs. 39 months) and OS (35 vs. 41 months) compared to lower cCPC% though it was not statistically significant.ConclusionFlow cytometric baseline cCPC% in newly diagnosed MM was associated with poor treatment response and survival.